Kestra Medical Technologies (KMTS) – Research Analysts’ Weekly Ratings Updates

Kestra Medical Technologies (NASDAQ: KMTS) recently received a number of ratings updates from brokerages and research firms:

• 9/16/2026 – Kestra Medical Technologies was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 9/15/2026 – Kestra Medical Technologies was given a new $30.00 price target by Royal Bank Of Canada.
• 9/15/2026 – Kestra Medical Technologies had its “overweight” rating reaffirmed by Piper Sandler.
• 9/15/2026 – Kestra Medical Technologies had its “buy” rating reaffirmed by BTIG Research. They now have a $32.00 price target on the stock.
• 9/12/2026 – Kestra Medical Technologies was downgraded by Wall Street Zen from “hold” to “sell”.
• 9/2/2026 – Kestra Medical Technologies had its “buy” rating reaffirmed by BTIG Research. They now have a $32.00 price target on the stock.
• 8/31/2026 – Kestra Medical Technologies was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 8/11/2026 – Kestra Medical Technologies was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 8/10/2026 – Kestra Medical Technologies is now covered by JPMorgan Chase & Co.. They set an “overweight” rating and a $30.00 price target on the stock.
• 8/8/2026 – Kestra Medical Technologies was upgraded by Wall Street Zen from “sell” to “hold”.

Insider Transactions at Kestra Medical Technologies

In other Kestra Medical Technologies news, Director Jeffrey Schwartz sold 3,890 shares of the company’s stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $25.18, for a total value of $97,950.20. Following the transaction, the director owned 7,019 shares of the company’s stock, valued at $176,738.42. This represents a 35.66% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Kevin Reilly sold 2,932 shares of the business’s stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $25.13, for a total transaction of $73,681.16. Following the completion of the sale, the director directly owned 5,368 shares in the company, valued at $134,897.84. This trade represents a 35.33% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 239,588 shares of company stock worth $5,802,688 in the last 90 days. Insiders own 5.30% of the company’s stock.

Kestra Medical Technologies, Inc is a medical device company focused on developing and commercializing technologies for patients at risk of sudden cardiac arrest. The company’s primary product is the ASSURE wearable cardioverter defibrillator, a wearable system designed to continuously monitor a patient’s heart rhythm and deliver an electrical shock when a life-threatening arrhythmia is detected.

The ASSURE system is intended to provide temporary protection for patients who may be at elevated risk of sudden cardiac death but are not yet candidates for, or are awaiting, an implantable cardioverter-defibrillator.